$ABEO earnings report

Abeona reports Q3 2026 ZEVASKYN net revenue of $13.5 million, up 18% sequentially, with net loss narrowing to $(4.8) million; cash fell to $134.9 million before a $30 million PIPE closed after quarter end. AlphAI read Abeona Therapeutics's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readABEO · Q3 2026 · ended 2026-09-30

Abeona reports Q3 2026 ZEVASKYN net revenue of $13.5 million, up 18% sequentially, with net loss narrowing to $(4.8) million; cash fell to $134.9 million before a $30 million PIPE closed after quarter end

→Mixed quarter

Product revenue rose 18% sequentially to $13.5 million and the quarterly net loss narrowed sharply from $(20.2) million in Q2 2026. Against that, cash, cash equivalents and short-term investments declined from $146.8 million to $134.9 million, the company acquired ABO-801 with $20 million of common stock issued and $30 million payable on FDA approval, and the filing gives no gross margin or guidance figure.

Revenue
$13.5M
ZEVASKYN (product revenue, net)
$13.5M
18% increase q/q

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net (Q3 2026)GAAP$13.5M18% increase–
Product revenue, net (Q3 2026, thousands)GAAP$13.49M––
Total revenues (Q3 2026)GAAP$13.49M––
Total revenues (nine months 2026)GAAP$33.59M––
Product revenue, net (nine months 2026)GAAP$33.59M––
License and other revenues (nine months 2025)GAAP— (nil)––
Cost of sales (Q3 2026)GAAP$5.7M––
Cost of sales (Q3 2026, thousands)GAAP$5.71M––
Cost of sales (nine months 2026)GAAP$12.59M––
Research and development (Q3 2026)GAAP$3.7M––
Research and development (Q3 2026, thousands)GAAP$3.67M––
Research and development (nine months 2026)GAAP$18.25M––
Selling, general and administrative (Q3 2026)GAAP$17.1M––
Selling, general and administrative (Q3 2026, thousands)GAAP$17.11M––
Selling, general and administrative (nine months 2026)GAAP$52.44M––
Total costs and expenses (Q3 2026)GAAP$26.49M––
Total costs and expenses (nine months 2026)GAAP$83.28M––
Loss from operations (Q3 2026)GAAP−$13.00M––
Loss from operations (nine months 2026)GAAP−$49.69M––
Interest income (Q3 2026)GAAP$2.26M––
Interest income (nine months 2026)GAAP$4.97M––
Interest expense (Q3 2026)GAAP−$557K––
Interest expense (nine months 2026)GAAP−$2.08M––
Change in fair value of warrant liabilities (Q3 2026)GAAP$6.51M––
Change in fair value of warrant liabilities (nine months 2026)GAAP$4.70M––
Gain from sale of priority review voucher, net (nine months 2025)GAAP— (nil)––
Income tax expense (benefit) (Q3 2026)GAAP$18K––
Income tax expense (benefit) (nine months 2026)GAAP$20K––
Net loss (Q3 2026)GAAP−$4.8M––
Net loss (Q3 2026, thousands)GAAP−$4.81M––
Net (loss) income (nine months 2026)GAAP−$42.07M––
Basic and diluted loss per common share (Q3 2026)GAAP$(0.08)––
Basic loss per common share (nine months 2026)GAAP$(0.74)––
Diluted loss per common share (nine months 2026)GAAP$(0.74)––
Cash, cash equivalents and short-term investments (September 30, 2026)GAAP$134.9M––
Total assets (September 30, 2026)GAAP$171.9M––
Total stockholders' equity (September 30, 2026)GAAP$125.9M––
ZEVASKYN patient treatments completed since launch (cumulative)other15––
ZEVASKYN patient treatments completed in Q3 2026other6––
ZEVASKYN QTC network sites (Q3 2026)othereight sites––

Segments

SegmentRevenueq/qy/y
ZEVASKYN (product revenue, net)The company states that broader qualified treatment center (QTC) participation supported increased ZEVASKYN treatment activity in the third quarter. Revenue was not recognized for one treatment because the associated batch did not meet the release criterion for the identity assay, as previously disclosed in August 2026.$13.5M18% increase–

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Abeona issued to Ellodi Pharmaceuticals $20 million of Abeona common stock at closing of the APT-1011 (ABO-801) asset purchase, with no upfront cash consideration.
  • Abeona entered into a securities purchase agreement for a private placement of $30 million in gross proceeds before fees and expenses; the company states the net proceeds are for general corporate purposes, including pipeline development and ZEVASKYN commercialization.
  • The September 30, 2026 cash balance excludes the $30 million in gross proceeds from the private placement completed after quarter end.

What drove it

  • The company attributes increased ZEVASKYN treatment activity in Q3 2026 to broader QTC participation, with Children's Hospital of Philadelphia and the University of Texas Medical Branch completing first treatments and increasing QTCs with treatment experience from two to four.
  • The QTC network was expanded to eight sites, including Cincinnati Children's (activated July 2026) and University of Florida Health (activated September 2026).
  • New Technology Add-On Payment (NTAP) status for ZEVASKYN became effective October 1, 2026. The company states this designation is expected to help support patient access and hospital adoption among eligible Medicare beneficiaries, who represent approximately 10 percent of RDEB patients.
  • Research and development expense fell to $3.7 million in Q3 2026 from $5.0 million in Q2 2026, and selling, general and administrative expense rose to $17.1 million from $15.8 million over the same two quarters.
  • Interest income of $2,263 thousand and a $6,507 thousand change in fair value of warrant liabilities are reported below operating loss in Q3 2026; the filing does not attribute these to specific causes.

Concerns

  • Cost of sales rose to $5.7 million in Q3 2026 from $4.2 million in Q2 2026, and the filing does not print a gross margin figure.
  • Cash, cash equivalents and short-term investments declined to $134.9 million from $146.8 million in Q2 2026 and from $191,404 thousand at December 31, 2025.
  • Revenue was not recognized for one treatment in Q3 2026 because the associated batch did not meet the identity assay release criterion. The forward-looking statements list manufacturing batch release, biopsy quality and the 84-hour shelf-life as risks to ZEVASKYN revenue.
  • The acquisition of ABO-801 includes $20 million of common stock issued at closing, $30 million payable upon FDA approval and up to an additional $30 million on sales milestones, plus tiered royalties on net sales ranging from low to mid teen percentages.
  • The $30 million private placement was completed after quarter end and is not reflected in the September 30, 2026 cash balance.
  • Interest expense and warrant fair value changes are reported together with operating results, and the filing gives no full-year outlook.

What to watch

  • Quarterly ZEVASKYN treatment count and the number of QTCs that complete treatments, against the cumulative total of 15 treatments and eight QTC sites reported.
  • Effect of NTAP status effective October 1, 2026 on hospital adoption and treatment activity, as the company describes it.
  • Cost of sales relative to product revenue in coming quarters, since no gross margin is printed.
  • Completion and final net proceeds of the $30 million private placement and the use of proceeds described by the company.
  • Cash position against the $134.9 million reported at September 30, 2026, before and after the private placement.
  • Progress of ABO-801 toward regulatory approval, which triggers the $30 million payment to Ellodi.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $134,941 thousand at September 30, 2026, compared with $191,404 thousand at December 31, 2025 and $146.8 million at June 30, 2026.
  • Total assets were $171,924 thousand at September 30, 2026, compared with $219,570 thousand at December 31, 2025.
  • Total liabilities were $46,048 thousand at September 30, 2026, compared with $60,354 thousand at December 31, 2025.
  • Total stockholders' equity was $125,876 thousand at September 30, 2026, compared with $159,216 thousand at December 31, 2025.
  • Common stock outstanding was 57,168,018 at September 30, 2026, compared with 55,043,413 at December 31, 2025.
  • Operating cash flow and free cash flow are not reported in the filing.

Analysis

Abeona reported Q3 2026 product revenue, net, of $13.5 million ($13,491 thousand in the statements), up 18% from $11.4 million in Q2 2026. The filing prints no prior-year Q3 product revenue, as the 2025 column shows a dash. Nine-month 2026 product revenue was $33,591 thousand. The company reports six ZEVASKYN treatments in Q3 2026 and 15 since launch, and states that broader QTC participation supported higher treatment activity. One treatment was not recognized as revenue because its batch did not meet the identity assay release criterion.

Costs moved in different directions. Cost of sales increased to $5,713 thousand from $4.2 million in Q2 2026, and the filing prints no gross margin figure, so margin cannot be read from the document. R&D fell to $3.7 million from $5.0 million in Q2 2026. SG&A rose to $17.1 million from $15.8 million. Total costs and expenses were $26,492 thousand in Q3 2026 against $24,018 thousand in Q3 2025, and loss from operations narrowed to $(13,001) thousand from $(24,018) thousand a year earlier. Net loss was $(4.8) million, or $(0.08) per share, compared with $(20.2) million, or $(0.35) per share, in Q2 2026 and $(5,161) thousand in Q3 2025. The filing does not attribute the sequential narrowing to a single cause, and the below-the-line items (interest income, interest expense and warrant fair value changes) were not explained by the company.

On the balance sheet, cash, cash equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30, 2026 and $191,404 thousand at December 31, 2025. The $30 million private placement closed after quarter end and is excluded from that balance. Total assets were $171,924 thousand and stockholders' equity was $125,876 thousand. Operating and free cash flow are not reported.

Capital allocation in the period was dominated by the ABO-801 acquisition from Ellodi Pharmaceuticals. The company issued $20 million of common stock at closing with no upfront cash, and agreed to pay $30 million on FDA approval and up to $30 million on sales milestones, plus royalties. Share count rose: common stock outstanding was 57,168,018 at September 30, 2026, against 55,043,413 at December 31, 2025. The company gives no revenue, margin or expense guidance in this filing, so no forward comparison is possible.

The key items for a reader are the sequential revenue increase, the narrower quarterly loss, the cash decline, and the absence of gross margin and cash flow disclosure. The NTAP designation effective October 1, 2026 is described by the company as expected to support access among eligible Medicare beneficiaries, who the filing says represent approximately 10 percent of RDEB patients.

Management, verbatim

Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience

Vish Seshadri, Ph.D., Chief Executive Officer, Abeona Therapeutics

Not in the filing

stated, not guessed
  • Gross margin for Q3 2026 and prior periods is not printed.
  • Prior-year (Q3 2025) product revenue value is shown as a dash in the statements, so the comparison is nil and no percentage change is printed.
  • Total revenues for Q2 2026 are not printed; only ZEVASKYN product revenue for Q2 2026 is given in the text.
  • Prior-quarter (Q2 2026) figures for interest income, interest expense, change in fair value of warrant liabilities, other income, income tax, total costs and expenses, and loss from operations are not printed.
  • Year-over-year and quarter-over-quarter percentage changes are not printed for any metric except the 18% sequential revenue increase, which is printed as a percentage without a dollar prior figure beyond the $11.4 million Q2 2026 value.
  • Operating cash flow, investing cash flow and free cash flow are not reported.
  • Company guidance or outlook for 2026 or later periods is not provided; no prior outlook was supplied for comparison.
  • Consensus estimates, analyst expectations and share-price reaction are not in the documents.
  • Net proceeds of the private placement and the number of shares issued in it are not printed.
  • Dec 31, 2025 comparatives for cash, total assets and equity are balance sheet items and are not presented as prior-year or prior-quarter figures in the key metrics.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readABEO · Second Quarter 2026 · ended June 30, 2026

Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million

→Mixed quarter

ZEVASKYN revenue and treatment activity advanced, while revenue-recognition and manufacturing-yield issues persisted, net loss widened sequentially, and cash, cash equivalents and short-term investments declined from December 31, 2025.

Revenue
11,380

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, netGAAP$11.38M31%–
License and other revenuesGAAP—––
Total revenuesGAAP11,380––
Cost of salesGAAP4,177––
RoyaltiesGAAP—––
Research and developmentGAAP5,021––
Selling, general and administrativeGAAP15,835––
Total costs and expensesGAAP25,033––
Loss from operationsGAAP(13,653)––
Interest incomeGAAP1,355––
Interest expenseGAAP(696)––
Change in fair value of warrant liabilitiesGAAP(7,191)––
Gain from sale of priority review voucher, netGAAP—––
Other (loss) income, netGAAP(6)––
Income (loss) before income taxesGAAP(20,191)––
Income tax expenseGAAP—––
Net (loss) incomeGAAP−$20.19M––
Basic (loss) income per common shareGAAP$ (0.35)––
Dilutive (loss) income per common shareGAAP$ (0.35)––
Weighted average number of common shares outstanding, basicGAAP57,048,385––
Weighted average number of common shares outstanding, dilutiveGAAP57,048,385––
Six-month product revenue, netGAAP$20.1M––
Six-month license and other revenuesGAAP—––
Six-month total revenuesGAAP20,100––
Six-month cost of salesGAAP6,873––
Six-month royaltiesGAAP—––
Six-month research and developmentGAAP14,576––
Six-month selling, general and administrativeGAAP35,337––
Six-month total costs and expensesGAAP56,786––
Six-month loss from operationsGAAP(36,686)––
Six-month interest incomeGAAP2,709––
Six-month interest expenseGAAP(1,526)––
Six-month change in fair value of warrant liabilitiesGAAP(1,805)––
Six-month gain from sale of priority review voucher, netGAAP—––
Six-month other income, netGAAP44––
Six-month income (loss) before income taxesGAAP(37,264)––
Six-month income tax expenseGAAP2––
Six-month net (loss) incomeGAAP−$37.27M––
Six-month basic (loss) income per common shareGAAP$ (0.66)––
Six-month dilutive (loss) income per common shareGAAP$ (0.66)––
Six-month weighted average number of common shares outstanding, basicGAAP56,835,833––
Six-month weighted average number of common shares outstanding, dilutiveGAAP56,835,833––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • Five patients were treated with ZEVASKYN during the second quarter of 2026, with revenue recognized for four treatments.
  • Three patients have completed treatments in the third quarter of 2026 to-date, and 12 patient treatments have been completed since launch.
  • NewYork-Presbyterian/Columbia University Irving Medical Center and Children’s Hospital of Philadelphia were activated as QTCs during the second quarter of 2026.
  • CHOP and University of Texas Medical Branch have commenced collection of patient biopsies, and CHOP has treated its first patient with ZEVASKYN.
  • Cincinnati Children’s was activated as a ZEVASKYN QTC in the third quarter of 2026.
  • Selling, general and administrative expenses decreased primarily due to fewer engineering runs and less manufacturing training costs in the second quarter of 2026.
  • Research and development expenses in the first quarter of 2026 included the one-time, up-front cost of $7.0 million for in-licensing ABO-701.

Concerns

  • Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications.
  • One batch yielded fewer than the threshold number of sheets for revenue recognition during the second quarter of 2026.
  • Net loss was $(20.2) million in the second quarter of 2026, compared to $(17.1) million in the first quarter of 2026.
  • The change in fair value of warrant liabilities was $(7,191) for the three months ended June 30, 2026.
  • Cash, cash equivalents and short-term investments were $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.

What to watch

  • Treatment completions and revenue recognition as the growing number of QTCs progress patients through the treatment process.
  • Manufacturing yield and the ability to produce ZEVASKYN batches that meet product release specifications.
  • The October 1, 2026 effective date for CMS New Technology Add-On Payment status for ZEVASKYN.
  • Hospital adoption and access for Medicare patients, who represent approximately 10 percent of RDEB patients.
  • Further QTC activations, patient biopsy collections, and patient treatments.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared to $191.4 million as of December 31, 2025.
  • Total assets: $ 179,507 as of June 30, 2026; $ 219,570 as of December 31, 2025.
  • Total liabilities: $ 51,449 as of June 30, 2026; $ 60,354 as of December 31, 2025.
  • Total stockholders’ equity: $ 128,058 as of June 30, 2026; $ 159,216 as of December 31, 2025.
  • Common stock outstanding: 57,225,919 as of June 30, 2026; 55,043,413 as of December 31, 2025.
  • Common stock and common stock equivalents: 71,098,537 as of June 30, 2026; 69,103,212 as of December 31, 2025.
  • Common stock warrants (pre-funded): 4,933,489 as of June 30, 2026; 5,113,321 as of December 31, 2025.
  • Common stock and pre-funded warrants: 62,159,408 as of June 30, 2026; 60,156,734 as of December 31, 2025.
  • Options to purchase common stock: 168,670 as of June 30, 2026; 176,019 as of December 31, 2025.
  • Conversion option to redeem common stock: 614,251 as of June 30, 2026; 614,251 as of December 31, 2025.
  • Warrants to purchase common stock: 8,156,208 as of June 30, 2026; 8,156,208 as of December 31, 2025.

Analysis

Abeona reported $11.4 million of net ZEVASKYN revenue in the second quarter of 2026, up 31% quarter-over-quarter from $8.7 million in the first quarter of 2026. Five patients were treated in the quarter and revenue was recognized for four treatments. Treatment activity continued into the third quarter, with three treatments completed to date, bringing completed treatments since launch to 12.

The revenue result also highlights commercial and manufacturing execution constraints. Revenue was not recognized for two patients due to low manufacturing yield or not meeting lot release specifications. In the second quarter, one batch yielded fewer than the threshold number of sheets required for revenue recognition. These issues make the relationship between patient treatments and recognized revenue a central operating measure.

Operating expenses moved lower sequentially in the reported expense categories discussed by the company. R&D expense was $5.0 million versus $9.6 million in the first quarter, which had included a one-time, up-front cost of $7.0 million for in-licensing ABO-701. SG&A was $15.8 million versus $19.5 million, primarily reflecting fewer engineering runs and less manufacturing training costs. Despite these reductions, net loss was $(20.2) million, compared with $(17.1) million in the first quarter, and the quarter included a $(7,191) change in fair value of warrant liabilities.

Commercial infrastructure expanded during and after the quarter. NewYork-Presbyterian/Columbia University Irving Medical Center and CHOP were activated in the second quarter, while Cincinnati Children’s was activated in the third quarter. CHOP and UTMB commenced patient-biopsy collections, and CHOP treated its first patient. CMS NTAP status becomes effective October 1, 2026 and is expected by the company to support hospital adoption and Medicare patient access.

Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, compared with $191.4 million as of December 31, 2025. The filing provided no quantitative financial guidance, operating cash flow, free cash flow, gross-margin disclosure, debt balance, repurchase activity, or dividend activity. Investor attention is therefore centered on treatment throughput, recognized revenue per completed treatment, manufacturing consistency, QTC patient onboarding, and the effect of NTAP status on access and hospital adoption.

Management, verbatim

Our confidence in ZEVASKYN’s substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of patients and expand our QTC network.

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

As early real-world experience with ZEVASKYN matures across activated sites, we expect to drive broader adoption and long-term growth.

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

Not in the filing

stated, not guessed
  • Forward financial guidance
  • Prior-quarter total revenue
  • Gross profit and gross margin
  • Non-GAAP financial measures
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Share repurchases
  • Dividends
  • Reportable segment revenue disclosure

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ABEO earnings dates

When is Abeona Therapeutics's next earnings date?
AlphAI has no date for ABEO yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.